TG Therapeutics Inc (TGTX)
Return on equity (ROE)
Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | -14,364 | 95,686 | 41,197 | 12,672 | -25,906 | -175,654 | -168,554 | -198,335 | -238,679 | -288,498 | -326,485 | -348,100 | -342,980 | -344,506 | -318,893 | -279,381 | -230,734 | -205,501 | -188,830 | -172,870 |
Total stockholders’ equity | US$ in thousands | 192,157 | 177,568 | 160,109 | 160,502 | 164,769 | 40,453 | 27,433 | 58,587 | 100,481 | 129,035 | 170,386 | 237,153 | 311,517 | 383,130 | 445,285 | 519,350 | 170,658 | 194,227 | -1,353 | 38,615 |
ROE | -7.48% | 53.89% | 25.73% | 7.90% | -15.72% | -434.22% | -614.42% | -338.53% | -237.54% | -223.58% | -191.61% | -146.78% | -110.10% | -89.92% | -71.62% | -53.79% | -135.20% | -105.80% | — | -447.68% |
September 30, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-14,364K ÷ $192,157K
= -7.48%
The return on equity (ROE) of TG Therapeutics Inc has displayed significant volatility over the past few quarters. The ROE has fluctuated between negative and positive values, indicating inconsistency in the company's ability to generate profit from shareholders' equity.
In the most recent quarter, ending September 30, 2024, the ROE was negative at -7.48%, reflecting a decrease from the previous quarter. This suggests that the company's profitability relative to its shareholders' equity deteriorated during this period.
Looking further back, the ROE had experienced a substantial improvement in the quarter ending June 30, 2024, reaching a relatively high value of 53.89%. This could indicate a period of strong profitability and efficiency in utilizing shareholders' equity to generate earnings.
However, the company has also encountered challenges in the past, as evidenced by extremely negative ROE figures in some quarters, such as the drastic declines in ROE in the quarters ending June 30, 2023, and March 31, 2023.
Overall, the fluctuating nature of TG Therapeutics Inc's ROE suggests inconsistency in the company's financial performance and efficiency in generating returns for its shareholders. Further analysis of the company's financial operations and strategies would be needed to understand the factors driving these fluctuations in ROE.
Peer comparison
Sep 30, 2024